
|Articles|July 31, 2006
Fourth indication approved for gemcitabine
Women with recurrent ovarian cancer will now have a new therapy option. Gemcitabine (Gemzar, Lilly) has been approved for use in combination with carboplatin for advanced ovarian cancer that has relapsed at least six months after initial therapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Addressing Depression Symptoms Can Significantly Improve Asthma Outcomes
2
How New Federal Spending Bill Bolsters CMS Oversight, PBM Transparency
3
Chronic Corticosteroid Use Harms Health, Increases Cost for Patients With Asthma
4
CagriSema Demonstrates Superior Hemoglobin and Weight Loss Results in Type 2 Diabetes
5























